↓ Skip to main content

Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report

Overview of attention for article published in BMC Cancer, October 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
reddit
1 Redditor

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report
Published in
BMC Cancer, October 2015
DOI 10.1186/s12885-015-1755-2
Pubmed ID
Authors

Laura L. Holman, Yulan Ren, Shannon N. Westin

Abstract

While peripheral neuropathy is a common side effect of platinum-based chemotherapy, central nervous system (CNS) toxicity, such as encephalopathy or seizures, appears to be rare. This manuscript describes the only reported case of nonconvulsive status epilepticus associated with cisplatin in a cervical cancer patient who does not have other underlying medical conditions. The patient is a 54-year-old Chinese female with recurrent stage IIIB moderately differentiated squamous cell carcinoma of the cervix who was being treated with cisplatin and topotecan. During the sixth cycle of this regimen, the patient presented with mental status changes. While imaging and laboratory values were within normal limits, the patient's EEG revealed nonconvulsive status epilepticus. After appropriate intervention, she made a complete recovery with no further seizures. The patient currently remains on antiepileptic therapy, but is no longer receiving cisplatin. Patients who present with new onset seizures should primarily be evaluated for underlying medical conditions. Among patients who are suspected to have CNS side effects associated with platinum use, we recommend avoidance of platinum agents in future chemotherapeutic regimens. Although rare, providers should be aware of the potential for CNS toxicity associated with this drug class.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 18%
Student > Master 2 18%
Student > Postgraduate 2 18%
Researcher 2 18%
Professor > Associate Professor 1 9%
Other 0 0%
Unknown 2 18%
Readers by discipline Count As %
Medicine and Dentistry 6 55%
Nursing and Health Professions 1 9%
Chemistry 1 9%
Business, Management and Accounting 1 9%
Unknown 2 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 October 2015.
All research outputs
#4,461,803
of 6,348,733 outputs
Outputs from BMC Cancer
#1,676
of 3,074 outputs
Outputs of similar age
#125,635
of 198,186 outputs
Outputs of similar age from BMC Cancer
#111
of 235 outputs
Altmetric has tracked 6,348,733 research outputs across all sources so far. This one is in the 26th percentile – i.e., 26% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,074 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,186 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 235 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.